In separate, live virtual events, David H. Aggen, MD, PhD; and Matthew R. Zibelman, MD, discussed the case of a patient with urothelial carcinoma and potential treatment options.
CASE SUMMARY
A man aged 74 years presents to his primary care physician reporting intermittent episodes of painless macrohematuria.
History
Focused Physical Exam
Evaluation by Urologic Oncologist
REFERENCE
1. Galsky MD, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274. J Clin Oncol. 2025;43(1):15-21. doi:10.1200/JCO.24.00340
Key Trials From ASH 2024 Impact Treatment for Plasma Cell Disorders Going Forward
February 20th 2025Peers & Perspectives in Oncology editorial board member Marc J. Braunstein, MD, PhD, FACP, discussed the significant advancements in multiple myeloma treatment at the 2024 ASH Annual Meeting and Exposition.
Read More